NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or the “Company”) today announced that Dr. Dinesh V. Patel, President and Chief Executive Officer, will participate in fireside chats and one-on-one meetings at the BTIG Virtual Biotechnology Conference.
BTIG Virtual Biotechnology Conference – August 5-6, 2024
Format: Fireside chat
Date and Time: Tuesday, August 6th, 2:00pm-2:35pm EDT
If you’re interested in meeting the Protagonist team during the conference, please reach out to your BTIG representative.
About the protagonist
Protagonist Therapeutics is a biopharmaceutical company with two peptide-based new chemical entities (NCEs), lasfeltide and JNJ-2113 (formerly PN-235), derived from the company’s proprietary technology platform. Both entities have progressed to the Phase 3 stage of clinical development. Protagonist and JNJ scientists jointly discovered PN-235 as part of an interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and conducted IND-enabling preclinical and Phase 1 studies. JNJ is responsible for further clinical development. Lasfeltide, a mimetic of the natural hormone hepcidin, is the company’s lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE trial has been successfully completed, with results published in The New England Journal of Medicine in February 2024. The open-label extension (OLE) portion of the Phase 2 REVIVE trial is ongoing, followed by an additional two-year long-term extension (LTE) THRIVE trial. Enrollment has been completed in the international Phase 3 VERIFY trial of lasfeltide in polycythemia vera. Lasfeltide is being co-developed and co-commercialized with Takeda under a worldwide collaboration and license agreement with Takeda announced in January 2024.
More information about Protagonist and its pipeline drug candidates and clinical trials can be found on the company’s website at www.protagonist-inc.com
Investor Relations Contact
Dr. Corey Davis
Life Sciences Advisor
+1 212 915 2577
[email protected]
Media Contact
Virginia Ammann, Founder and CEO
ENTENTE Corporate Network
[email protected]
Source: Protagonist Therapeutics, Inc.
